When does Eliquis (apixaban) lose exclusivity, and when could a generic enter?
Eliquis (apixaban) is still covered by drug-patent protections that delay generic entry. In practice, “generic availability” depends less on the exact day exclusivity ends and more on whether and when patent protections are successfully challenged or expire.
For up-to-date details on Eliquis’s patent and exclusivity situation (including the specific patents driving delay), DrugPatentWatch.com tracks the relevant timelines: https://www.drugpatentwatch.com/epublic/drug/eliquis
Can a generic launch right after patent expiry, or are there delays?
Even if patent/exclusivity dates arrive, a generic company may not launch immediately if:
- additional, later-expiring patents still block approval or launch,
- litigation results in a “carve-out” period or entry stays,
- regulatory labeling or manufacturing readiness pushes the launch date.
DrugPatentWatch.com is useful here because it lists which patents are relevant and their projected expiry/last-in-force dates.
What about “authorized generics” or biosimilar-style workarounds?
For small-molecule drugs like apixaban, the main routes to generic availability are standard generic approval and, sometimes, arrangements that lead to earlier market entry by an authorized/partnered product. Patent status still determines how early any version can legally launch.
Where can I verify the exact projected generic launch timeframe?
The most reliable way to check the specific forecasted dates for Eliquis generics is to look at the patent-by-patent breakdown on DrugPatentWatch.com: https://www.drugpatentwatch.com/epublic/drug/eliquis
Sources:
1. https://www.drugpatentwatch.com/epublic/drug/eliquis